Severe Aplastic Anaemia Working Party (SAAWP)
Study type:
Study number:
84090095
Type of treatment:
Allogénique
Diseases:
Aplasie Médullaire
Short title:
Résultats de la greffe chez les patients âgés atteints de SAA
Primary objective:
Décrire les résultats des patients atteints d'aplasie médullaire sévère (SAA) ayant reçu une greffe allogénique entre 2010 et 2020, en analysant spécifiquement l'impact de l'âge (notamment chez les patients de plus de 40 ans) sur la survie globale (OS).
Key inclusion criteria:
Country:
All EBMT member countries
Principal investigator:
Antonio Risitano
EBMT Study coordinator:
Brian Piepenbroek
Study coordinator email:
saawp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results